Interventional cardiology in Israel at 2005—state of practice

References

• Silber S., Albertsson P., Aviles F. F., et al. Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur Heart J 2005; 26: 804–47
   Google Scholar
• Smith S., Feldman T. E., Hirshfeld J. W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 21: e166–286
   Google Scholar
• Hill R., Bagust A., Bakhai A., Dickson R., Dundar Y., Haycox A., et al. Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess 2004; 8: iii–iv; 1–242
   PubMed Web of Science ®Google Scholar
• Ijsselmuiden A. J., Tangelder G. J., Cotton J. M., Vaijifdar B., Kiemeneij F., Slagboom T., et al. Direct coronary stenting compared with stenting after predilatation is feasible, safe, and more cost‐effective in selected patients: evidence to date indicating similar late outcomes. Int J Cardiovasc Intervent 2003; 5: 143–50
   PubMedGoogle Scholar
• Ijsselmuiden A. J., Serruys P. W., Scholte A., Kiemeneij F., Slagboom T., vd Wieken L. R., et al. Direct coronary stent implantation does not reduce the incidence of in‐stent restenosis or major adverse cardiac events: six month results of a randomized trial. Eur Heart J 2003; 24: 421–9
   PubMed Web of Science ®Google Scholar
• Hill R., Bagust A., Bakhai A., Dickson R., Dundar Y., Haycox A., et al. Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess 2004; 8: iii–iv; 1–242
   PubMed Web of Science ®Google Scholar
• Kaiser C., Brunner‐La Rocca H. P., Buser P. T., Bonetti P. O., Osswald S., Linka A., , BASKET Investigators, et al. Incremental cost‐effectiveness of drug‐eluting stents compared with third‐generation bare‐metal stent in a real‐world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005; 366: 921–9
   PubMed Web of Science ®Google Scholar
• Bagust A., Grayson A. D., Palmer N. D., Perry R. A., Walley T. Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost‐utility study. Heart 2006; 92: 68–74
   PubMed Web of Science ®Google Scholar
• Mueller C., Hodgson J. M., Schindler C., Perruchoud A. P., Roskamm H., Buettner J. Cost‐effectiveness of intracoronary ultrasound for percutaneous coronary interventions. Am J Cardiol 2003; 91: 143–7
   PubMed Web of Science ®Google Scholar
• Gaster A. L., Slothuus U., Larsen J., Thayssen P., Haghfelt T. Cost‐effectiveness analysis of intravascular ultrasound guided percutaneous coronary intervention versus conventional percutaneous coronary intervention. Scand Cardiovasc J 2001; 35: 80–5
   PubMed Web of Science ®Google Scholar
• Fearon W. F., Yeung A. C., Lee D. P., Yock P. G., Heidenreich P. A. Cost‐effectiveness of measuring fractional flow reserve to guide coronary interventions. Am Heart J 2003; 145: 882–7
   PubMed Web of Science ®Google Scholar
• Berry E., Kelly S., Hutton J., Lindsay H. S., Blaxill J. M., Evans J. A., et al. Intravascular ultrasound‐guided interventions in coronary artery disease: a systematic literature review, with decision‐analytic modelling, of outcomes and cost‐effectiveness. Health Technol Assess 2000; 4: 1–117
   PubMedGoogle Scholar
• Exaire J. E., Tcheng J. E., Kereiakes D. J., Kleiman N. S., Applegate R. J., Moliterno D. J., ELECT Investigators. Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel. Catheter Cardiovasc Interv 2005; 64: 369–72
   PubMed Web of Science ®Google Scholar
• Lincoff A. M., Bittl J. A., Harrington R. A., , REPLACE‐2 Investigators, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE‐2 randomized trial. JAMA 2003; 289: 853–63
   PubMed Web of Science ®Google Scholar
• Ferguson J. J., Califf R. M., Antman E. M., , SYNERGY Trial Investigators, et al. Enoxaparin vs unfractionated heparin in high‐risk patients with non‐ST‐segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292: 45–54
   PubMed Web of Science ®Google Scholar
• Brener S. J., Moliterno D. J., Lincoff A. M., Steinhubl S. R., Wolski K. E., Topol E. J. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 2004; 110: 994–8
   PubMed Web of Science ®Google Scholar
• Stone G. W., McLaurin B. T., Cox D. A., Bertrand M. E., Lincoff A. M., Moses J. W., , ACUITY Investigators, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203–16
   PubMed Web of Science ®Google Scholar
• Denardo S. J., Davis K. E., Tcheng J. E. Elective percutaneous coronary intervention using broad‐spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other anti‐thrombin therapy. Am Heart J 2005; 149: 138–44
   PubMed Web of Science ®Google Scholar
• The CHAO study – Presented at the TCT meeting 10‐27‐06 and posted at TCTMD.COM.
   Google Scholar
• Montalescot G., White H. D., Gallo R., Cohen M., Steg P. G., Aylward P. E., , STEEPLE Investigators, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355: 1006–17
   PubMed Web of Science ®Google Scholar
• Moscucci M., Fox K. A., Cannon C. P., et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24: 1815–23
   PubMed Web of Science ®Google Scholar
• Fischell T. A., Attia T., Rane S., Salman W. High‐dose, single‐bolus eptifibatide: a safe and cost‐effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions. J Invasive Cardiol 2006; 18: 487–91
   PubMedGoogle Scholar
• Agema W. R., Monraats P. S., Zwinderman A. H., De Winter R. J., Tio R. A., Doevendans P. A., et al. Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre‐drug‐eluting stent era. Eur Heart J 2004; 25: 1163–70
   PubMed Web of Science ®Google Scholar
• Hillegass W. B., Newman A. R., Raco D. L. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non‐ST‐segment elevation acute coronary syndromes. Estimating the economic implications. Pharmacoeconomics 2001; 19: 41–55
   PubMed Web of Science ®Google Scholar
• Reed S. O., Mullins C. D., Magder L. S. Cost effectiveness of abciximab during routine medical practice. Pharmacoeconomics 2000; 18: 265–74
   PubMed Web of Science ®Google Scholar
• Zwart‐van Rijkom J. E., van Hout B. A. Cost‐efficacy in interventional cardiology; results from the EPISTENT study Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial. Eur Heart J 2001; 22: 1476–84
   PubMed Web of Science ®Google Scholar
• Milkovich G., Gibson G. Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention. Am J Health Syst Pharm 2003; 60: S15–21
   PubMed Web of Science ®Google Scholar
• Le May M. R., Davies R. F., Labinaz M., Sherrard H., Marquis J. F., Laramee L. A., et al. Hospitalization costs of primary stenting versus thrombolysis in acute myocardial infarction: cost analysis of the Canadian STAT Study. Circulation 200325; 108: 2624–30
   PubMed Web of Science ®Google Scholar
• Hartwell D., Colquitt J., Loveman E., Clegg A. J., Brodin H., Waugh N., et al. Clinical effectiveness and cost‐effectiveness of immediate angioplasty for acute myocardial infarction: systematic review and economic evaluation. Health Technol Assess 2005; 9: 1–99; iii–iv
   Web of Science ®Google Scholar
• Yee K. M., Lazzam C., Richards J., Ross J., Seidelin P. H. Same‐day discharge after coronary stenting: a feasibility study using a hemostatic femoral puncture closure device. J Interv Cardiol 2004; 17: 315–20
   PubMedGoogle Scholar
• Knopf W. D., Cohen‐Bernstein C., Ryan J., Heselov K., Yarbrough N., Steahr G. Outpatient PTCA with same day discharge is safe and produces high patient satisfaction level. J Invasive Cardiol 1999; 11: 290–5
   PubMed Web of Science ®Google Scholar
• Clement‐Major S., Lemire F. Is outpatient coronary angioplasty and stenting feasible and safe? Results of a retrospective analysis. Can J Cardiol 2003; 19: 47–50
   PubMed Web of Science ®Google Scholar
• Slagboom T., Kiemeneij F., Laarman G. J., van der Wieken R., Odekerken D. Actual outpatient PTCA: results of the OUTCLAS pilot study. Catheter Cardiovasc Interv 2001; 53: 204–8
   PubMed Web of Science ®Google Scholar
• Anderson H. V., Shaw R. E., Brindis R. G., Hewitt K., Krone R. J., Block P. C., et al. A contemporary overview of percutaneous coronary interventions. The American College of Cardiology‐National Cardiovascular Data Registry (ACC‐NCDR). J Am Coll Cardiol 2002; 39: 1096–103
   PubMed Web of Science ®Google Scholar
• Anderson H. V., Shaw R. E., Brindis R. G., Klein L. W., McKay C. R., Kutcher M. A., et al. Relationship between procedure indications and outcomes of percutaneous coronary interventions by American College of Cardiology/American Heart Association Task Force Guidelines. Circulation 2005; 112: 2786–91
   PubMed Web of Science ®Google Scholar
• Lenzen M. J., Boersma E., Bertrand M. E., Maier W., Moris C., Piscione F., , European Society of Cardiology, et al. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. Eur Heart J 2005; 26: 1169–79
   PubMed Web of Science ®Google Scholar
• Leon MB. An evidence base medicine appraisel of indications for drug eluting stents‐ appropriate use abuse and uncertainties. Presented at tct.com www.tctmd.com/csportal/appmanager/tctmd/main?_nfpb = true&_pageLabel = TCTMDContent.
   Google Scholar
• Scholte op Reimer W, Simoons MV, Boersma E, Gitt AK. Euro Heart Survey‐ Cardiovascular disease in Europe 2006 35–35. Published at escardio.org: http://www.escardio.org/NR/rdonlyres/1801646F‐79EB‐4891‐84D1‐D7DC05A8AA8A/0/EHS_Euro_Heart_Survey_CVD_report_2006.pdf.
   Google Scholar